SeraNovo and Graviton deepen collaboration and enter into a second license agreement to develop formulations for Graviton's ROCK-2 inhibitors
Venture Challenge Winner SeraNovo is pleased to announce the closing of a second license agreement with Graviton Bioscience Corporation (Graviton), a biopharmaceutical company engaged in the research and development of small molecules in the fields of oncology and neuroscience. Under the agreement, SeraNovo will license its deep eutectic solvent technology for the formulation of Graviton’s ROCK-2 inhibitors.
Niall Hodgins, SeraNovo’s Chief Executive Officer commented:
“We are delighted to enter into this second license agreement with Graviton. We already have one joint program that will go into the clinic in the near future, and we are now broadening the scope of our collaboration to cover all of Graviton’s ROCK-2 inhibitors. This collaboration provides robust evidence of efficacy for our formulation platform”.